Hepatitis

Hepatitis study information presented at conference

Published in AIDS Weekly, November 22nd, 2004

New studies evaluating the hepatitis C treatment Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP), including Roche's head-to-head study evaluating the impact of Pegasys versus Peg-Intron on patients' hepatitis C virus levels up to the eighth week of therapy, was presented at the 55th American Association for the Study of Liver Diseases Annual Meeting.

The meeting will bring together leading hepatologists and gastroenterologists to discuss the latest clinical research about hepatitis C and liver disease.

Hepatitis C is a blood-borne virus that chronically infects an estimated 2.7 million Americans. The virus is a leading cause of cirrhosis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2004-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry